Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McKesson Corporation (MCK) vs ProShares UltraPro S&P500 (UPRO) Price & Performance

McKesson CorporationTrade
ProShares UltraPro S&P500Trade

Price performance (Past 24H)

Key statistics

McKesson Corporation vs ProShares UltraPro S&P500 — how do they compare? McKesson Corporation trades at $899.06 (market cap $102.58B), while ProShares UltraPro S&P500 trades at $154. The key difference: McKesson Corporation pays a 0.43% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.

MCKUPRO
Market Cap
$102.58B
Sector
HealthLeveraged / Inverse
52-Week High
$995.69$155.10
52-Week Low
$659.01$89.29
Enterprise Value
$109.12B
Dividend Yield
0.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McKesson Corporation

McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.

Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.

ProShares UltraPro S&P500

UPRO trades at $155.10, up 1.72% on the day, with a bullish technical signal from moving averages and a neutral oscillator reading. The stock faces resistance near $156 and support at $154, while the RSI indicates potential overbought conditions. Recent news highlights S&P 500 strength, with JPMorgan raising its 2026 target to 8,000, driven by AI-driven earnings growth and robust corporate performance.

The outlook remains positive amid strong market momentum, but risks include overvaluation concerns and sensitivity to economic data. Upside potential hinges on sustained earnings growth, while pullbacks may occur if breadth weakens or inflation fears resurface.

Returns comparison

Trailing returns across standard periods

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK

About ProShares UltraPro S&P500

UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.

Read more on UPRO